INV322 / Invenra - LARVOL DELTA

INV322, a TME selective CD25 x CTLA4 bispecific antibody approach for depletion of tumor restricted Tregs (SITC 2022) - "IND-enabling activities are underway with INV322. Ethics Approval All animal studies were reviewed and approved under Invenra's IACUC protocol (I-RP-A-07)."

IO biomarker • Oncology • Solid Tumor • CTLA4 • IL2RA

Invenra to Present Preclinical Data on INV322, A Next Generation Tumor Treg Depleter (Businesswire) - "Invenra...will present preclinical data supporting the ongoing development of INV322, an antibody-based cancer therapeutic. The preclinical research findings will be presented at the 13th Annual World Bispecific Summit, Thursday, September 22nd, 2022 and at the Immuno-Oncology Summit, Wednesday, October 12th, 2022, both in Boston....The presentation will highlight preclinical data related to the lead candidate INV322, a SNIPER™ Bispecific Antibody co-targeting CTLA-4 and CD25....In vivo studies using a murine surrogate also show potent anti-tumor responses after a single dose and selective regulatory T cell (Treg) depletion in syngeneic mice. Moreover, synergistic anti-tumor activity was also observed in combinations with anti-PD-1 and anti-PD-L1 agents."

Preclinical • Oncology